These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26438471)

  • 1. The Effect of Testosterone Topical Solution in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel.
    Burns PR; Kim ED; Ruff DD; Seftel AD
    Am J Mens Health; 2018 May; 12(3):524-530. PubMed ID: 26438471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
    Grober ED; Khera M; Soni SD; Espinoza MG; Lipshultz LI
    Int J Impot Res; 2008; 20(2):213-7. PubMed ID: 17898800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
    Blick G
    Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of Testim gel.
    McNicholas T; Ong T
    Expert Opin Pharmacother; 2006 Mar; 7(4):477-84. PubMed ID: 16503819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function.
    McNicholas TA; Dean JD; Mulder H; Carnegie C; Jones NA
    BJU Int; 2003 Jan; 91(1):69-74. PubMed ID: 12614254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new 2% testosterone gel formulation: a comparison with currently available topical preparations.
    Arver S; Stief C; de la Rosette J; Jones TH; Neijber A; Carrara D
    Andrology; 2018 May; 6(3):396-407. PubMed ID: 29600542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.
    Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Berman N; Hull L; Swerdloff RS
    J Clin Endocrinol Metab; 2004 May; 89(5):2085-98. PubMed ID: 15126525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men.
    Kaufman JM; Miller MG; Garwin JL; Fitzpatrick S; McWhirter C; Brennan JJ
    J Sex Med; 2011 Jul; 8(7):2079-89. PubMed ID: 21492400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS).
    Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
    J Sex Med; 2011 Nov; 8(11):3204-13. PubMed ID: 21834870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testosterone 2% gel can normalize testosterone concentrations in men with low testosterone regardless of body mass index.
    Dobs A; Norwood P; Potts S; Gould E; Chitra S
    J Sex Med; 2014 Mar; 11(3):857-64. PubMed ID: 24283410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption of testosterone gel 1% (Testim) from three different application sites.
    Guay AT; Smith TM; Offutt LA
    J Sex Med; 2009 Sep; 6(9):2601-10. PubMed ID: 19549089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning.
    Seftel AD; Mack RJ; Secrest AR; Smith TM
    J Androl; 2004; 25(6):963-72. PubMed ID: 15477371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of a single serum testosterone measurement to determine response to topical testosterone replacement in hypogonadal men.
    Muram D; Ni X
    Curr Med Res Opin; 2016; 32(2):263-9. PubMed ID: 26549704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men.
    Wang C; Swerdloff RS; Iranmanesh A; Dobs A; Snyder PJ; Cunningham G; Matsumoto AM; Weber T; Berman N;
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2839-53. PubMed ID: 10946892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year efficacy and safety study of a 1.62% testosterone gel in hypogonadal men: results of a 182-day open-label extension of a 6-month double-blind study.
    Kaufman JM; Miller MG; Fitzpatrick S; McWhirter C; Brennan JJ
    J Sex Med; 2012 Apr; 9(4):1149-61. PubMed ID: 22321357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparability of single measurements of serum testosterone to the 24-hour C(avg) in patients using testosterone 2% solution.
    Muram D; Baygani S
    J Sex Med; 2014 Nov; 11(11):2826-9. PubMed ID: 25123851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compounded percutaneous testosterone gel: use and effects in hypogonadal men.
    Cutter CB
    J Am Board Fam Pract; 2001; 14(1):22-32. PubMed ID: 11206690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale, design and methods of the ESPRIT study: Energy, Sexual desire and body PropoRtions wIth AndroGel, Testosterone 1% gel therapy, in hypogonadal men.
    Behre HM; Heinemann L; Morales A; Pexman-Fieth C
    Aging Male; 2008 Jun; 11(2):101-6. PubMed ID: 18570063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim, compared to AndroGel.
    Marbury T; Hamill E; Bachand R; Sebree T; Smith T
    Biopharm Drug Dispos; 2003 Apr; 24(3):115-20. PubMed ID: 12673669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: efficacy and treatment cost.
    Taylor F; Levine L
    J Sex Med; 2010 Jan; 7(1 Pt 1):269-76. PubMed ID: 19694928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.